Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai and Selvita agree new cancer research alliance

Eisai and Selvita agree new cancer research alliance

18th September 2013

Eisai has announced that its US-based subsidiary H3 Biomedicine has entered into an oncology-focused research collaboration with the eastern European drugmaker Selvita.

The alliance will see both companies working to create novel anticancer agents through the identification and validation of several kinases as therapeutic targets for cancers with specific genetic characteristics.

This will leverage H3's unique tools and research engines in bioinformatics as well as Selvita's robust kinase discovery platform, helping to identify genes that are the root causes of cancer and developing effective new treatments on this basis.

It is hoped that the agreement will complement the technological bases of both companies and accelerate validation of the importance and druggability of kinase targets for cancer treatment.

A company statement said: "Eisai shares the ambitious drug discovery vision upheld by H3 Biomedicine and will continue to make contributions by delivering highly efficacious, innovative treatments to patients living with cancer worldwide."

This comes after Eisai had a promising new treatment for lymphatic filariasis – a neglected tropical disease – granted prequalification status from the World Health Organization last month.ADNFCR-8000103-ID-801638791-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.